DoD awards $6.42M to Roswell Park Comprehensive Cancer Center
AIM ImmunoTech announced the U.S. DOD)has granted a four-year, $6.42 million "Breakthrough Award" to Roswell Park Comprehensive Cancer Center for a clinical study of a combination of therapies, including the company's drug Ampligen, in patients with brain-metastatic breast cancer. September 19, 2019